drugset
drugset / Trial / NCT03977974

A Study of LY3526318 in Healthy Participants

NCT03977974 ↗

Phase 1 Terminated 76 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety and side effects of LY3526318 when given by mouth to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 28 days and Part B will last up to 51 days, including screening and follow-up.

Timeline

Start
2019-06-21
Primary completion
2020-03-05
Completion
2020-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3526318 Unknown 10 mg Oral
Subject LY3526318 Unknown 30 mg Oral
Subject LY3526318 Unknown 50 mg Oral
Subject LY3526318 Unknown 60 mg Oral
Subject LY3526318 Unknown 100 mg Oral
Subject LY3526318 Unknown 200 mg Oral
Subject LY3526318 Unknown 300 mg Oral

Indications

No indication recorded.